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Abstract
On April 7,8, 2009 a Symposium entitled "Pathophysiology of Successful and Unsuccessful Ageing"
took place in Palermo, Italy. Here, the lectures of G. Pawelec, D. Dunn-Walters and. G. Colonna-
Romano on T and B immunosenescence are summarized. In the elderly, many alterations of both
innate and acquired immunity have been described. Alterations to the immune system in the older
person are generally viewed as a deterioration of immunity, leading to the use of the catch-all term
immunosenescence. Indeed, many immunological parameters are often markedly different in
elderly compared to young people, and some, mostly circumstantial, evidence suggests that
retained function of both innate and acquired immunity in the elderly is correlated with health
status. What is often not clear from studies is how far immune dysfunction is a cause or an effect.
A better understanding of immunosenescence and mechanisms responsible for proven deleterious
changes is needed to maintain a healthy state in later life and to design possible therapeutic
interventions.
Background
The immune system of older people is usually perceived
as declining in fidelity and efficiency with age, resulting in
an increased susceptibility to infectious diseases and path-
ological conditions relating to inflammation (e.g. cardio-
vascular disease, Alzheimer's disease) or autoreactivity
(e.g. rheumatoid arthritis). This overall change in immu-
nity is loosely termed "immunosenescence". The individ-
ual contributing factors to immunosenescence are many
and varied, due to the multi-factorial complexity of the
immune system. It is often difficult to determine whether
changes in a particular cell type are intrinsic to that cell, or
caused by environmental changes, or both. This is partic-
ularly the case for lymphocytes, where the interplay
between B cells and T cells is crucial for effective
responses, so if one subset is affected it will change the
function of the other one [1-3].
Impact of Cytomegalovirus (CMV) infection on 
immunosenescence
Anecdotally, the clinical relevance of immunosenescence
is well-documented, but exact detailed information is, in
fact, hard to come by. Immunosenescence is a very
vaguely-defined descriptive term covering the deleterious
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age-associated changes to immunity observed in all mam-
mals studied so far. As immunity almost certainly evolved
to protect against infectious disease, which is a major
cause of reduced lifespan, correlations between immune
function and longevity have been sought for many years.
Early studies indicated that responses to mitogens pre-
dicted mortality to some degree, and since then many
studies have probed associations between survival and
parameters of both innate and acquired immunity. An
emerging consensus suggests that maintenance of appro-
priate immunity is essential for exceptional longevity and,
by implication, also for "normal" longevity [4]. While all
components of innate and acquired immunity are
changed with age, the clinical impact of these changes is
not clear, and mechanisms of and markers for immunose-
nescence are controversial. In humans, cross-sectional
study design raises many difficulties – potentially con-
founding the interpretation of the published data. Exam-
ining immune status in the current elderly is rather like an
astronomer examining the far-away cosmos: we are seeing
the results of events that happened a long time ago, when
circumstances were different from those applicable nowa-
days. These differences, which cannot be controlled for,
include genetics, environment, nutrition, developmental
variables and pathogen load [5]. The advantages and dis-
advantages of longitudinal studies on the same individu-
als emerged in the context of the pioneering OCTO/
NONA studies of people >85 yr of age, which resulted in
the definition of an "immune risk profile" (IRP) [5-8].
Although this is a concept which has become increasingly
accepted of late, it should be emphasized that the IRP has
only been shown to predict mortality in very elderly
Swedes, on the basis of very limited data. These studies
must be repeated and performed in other populations
too. On the basis of even less data, we can say that it seems
that the IRP is not predictive of excess mortality at 55 yr
baseline, but might start to become so at 65 yr (on 10-yr
follow-up). Because one very strong influence on the IRP
is infection with CMV, it will be extremely important to
test whether immune signatures like the IRP are informa-
tive under other circumstances, in different populations,
and whether polypathogenicity has an additive effect.
There is some epidemiological evidence for excess mortal-
ity in CMV-positive populations, which is further
increased in those co-infected with hepatitis A and B as
well. There is also some emerging evidence that CMV anti-
body titer may also be informative in this regard: individ-
uals in the upper quartile had significantly reduced
survival times compared to those in the lower quartile.
The marked influence of CMV on immune signatures is
illustrated in the finding that cross-sectional studies on
several different European populations clearly indicate
that the consensus view of T cell immunosenescence (that
the fraction of naïve CD8 cells decreases in the elderly and
the fraction of late-differentiated memory cells increases)
does indeed hold true – but only for people who are
infected with CMV. Such individuals also have higher lev-
els of C-reactive protein, indicating that they are more
likely to suffer "inflammaging", itself linked with
increased occurrence of diabetes and other inflammatory
diseases, as well as general frailty and increased mortality.
This too may therefore be markedly influenced by CMV.
Infection with other persistent herpesviruses, at least EBV,
HSV and VSV, does not appear to have any similar effect
[5,9]. The uniqueness of CMV in this context remains
enigmatic. We propose that there may have been some
advantage in early life to being CMV-positive – possibly
precisely because of the enhanced pro-inflammatory sta-
tus in infected people which might have had a protective
effect against infection with other pathogens under condi-
tions in the wild. It is thus concluded that immune signa-
tures are indeed informative for "immunosenescence",
which predicts mortality, but that these immune signa-
tures are materially influenced by CMV infection [10].
Any immunogerontological study must therefore take
CMV status into account. Although immunosenescence is
clearly not caused by CMV, if only because not all elderly
people are CMV-positive, this infectious agent seems to
have a large impact on immune parameters in later life
and may contribute to increased morbidity and eventual
mortality. If truly carrying a benefit in early life, this
would be yet another example of "antagonistic pleiot-
ropy" which seems almost to constitute one of the few
general laws of ageing [11].
B immunosenescence
Literature on immunosenescence has focused mainly on T
cell impairment, but the B cell compartment is also
affected in aged. The quality of the antibody response is
substantially impaired. Until recently it was considered
that the most likely cause of B cell failure was a lack of
effective T cell help in a T-dependent reaction. Thymic
involution is well known, and there is a substantial litera-
ture on the functional decline of T cells with age. How-
ever, there are T-independent functions of B cells, such as
the polysaccharide responses that are crucial for anti-bac-
terial protection, which also appear to be lacking in later
life. Additionally, there is emerging evidence to suggest
that B cells are important antigen presenting cells in their
own right and can be key regulators of T cell development,
leading us to speculate that some of the failures of T cell
function may yet be blamed on insufficient help from B
cells! Changes in B cell number and repertoire have been
described, and decreased IgM and IgD levels in the elderly
suggest a shift from the naïve (CD27-) compartment of
the B cell branch towards the memory (CD27+) compart-
ment. However, these data are controversial since not all
studies have shown this [12-14].Immunity & Ageing 2009, 6:10 http://www.immunityageing.com/content/6/1/10
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Circulating B cells can be divided on the basis of their
expression of IgD and CD27 into different functional sub-
sets. In the aged, a double-negative (DN) IgD-CD27- B
cell subset is significantly increased [14]. Most of these
cells are IgG+. Preliminary data on telomere length and
expression of the ABCB1 transporter and anti-apoptotic
molecule, Bcl2, suggest that DN cells have the markers of
memory B cells. Furthermore, these cells do not seem to
act as antigen presenting cells, nor do they express signifi-
cant levels of the CD40 molecule necessary to interact
with T lymphocytes through the ligand, CD154. Hence,
these expanded cells may be late memory or exhausted
cells that have down-modulated the expression of CD27
and filled the immunologic space in the elderly. These
cells might be the age-related manifestation of time-
enduring stimulation or dysregulation of the immune sys-
tem [14]. Interestingly this DN B cell population is
increased also in patients affected by Lupus [15] and in
healthy subjects challenged with respiratory syncitial virus
(RSV) [16].
Of interest, B naïve lymphocytes are increased in the off-
spring of healthy centenarians [17]. It is well known that
older offspring of centenarians, who are in their 70 s and
80 s, have a survival advantage when compared with con-
trol subjects of the same age range whose parents died at
an average life expectancy [18]. The main lymphocyte dif-
ferences observed between the two groups concern B cells.
Indeed naïve B cells are more abundant in centenarian off-
spring. These data are similar to that found in previous
studies on younger subjects. So, the B cell compartment of
the older offspring of centenarians seems to have more in
common with that of younger controls than with control
subjects of a similar age [17].
Human B cell repertoire diversity in old age
It is clear that the humoral immune response to challenge
is impaired in later life, since the titre and affinity of anti-
bodies raised by vaccination are consistently lower for a
variety of different vaccine challenges [19]. The actual
number of B cells does not appear to change with age in
proportion to the decrease in vaccine efficiency. In fact, in
mice, there is little evidence for any change in overall B
cell numbers. Yet there are reports of perturbations in the
germinal centre (GC) reaction, which is key to the devel-
opment of effective B cells in a T-dependent response.
Some groups studying mice have reported a decrease in
the size and number of GCs responding to challenge [20].
Other studies in humans have not shown any difference
in GC number [21], but have shown more subtle differ-
ences in the dynamics of the response within the individ-
ual GCs [22]. The strength of selection in the affinity
maturation process within the germinal centre was shown
to decrease with age in the germinal centres of Peyer's
patches in the gut. This was not seen in those of the
spleen, so there are tissue-specific differences occurring
that are not always easy to elucidate in humans [22]. A
decrease in function of GCs in the gut could be due to a
number of factors. Availability of T cell help is an obvious
one, although we did not see any differences in the num-
bers of CD4+ T cells present in these follicles [21].
Diversity of the available pool of B cells is another possi-
ble factor. It has been shown in mice that the lymphoid
lineage is decreased at the expense of the myeloid lineage
and the bone marrow B cell output decreases with age
[23]. Although this has not been shown in humans it is a
strong possibility. A decreased output of naïve B cells, cou-
pled with the accumulation of memory cells from previ-
ous immune challenges along the lifecourse, may well
result in a reduction of B cell diversity. This would be espe-
cially true in the mucosal immune system where the anti-
genic challenge is frequent. Loss of diversity in a
population of B cells would theoretically impair the B cell
response to new challenges as the available repertoire
from which to find an effective responder would be
decreased. This would be particularly important if, as sug-
gested, a larger proportion of the population are memory
cells that had already been through the affinity matura-
tion process [14]. Their B cell receptors would be more
specific for a particular antigen and may therefore have
lost the flexibility of their antigen binding site that might
have otherwise allowed them to accommodate a broader
range of antigens. B cell diversity in the peripheral blood
of participants from the Swedish "NONA" longitudinal
study using a method of B cell spectratyping was recently
explored. This takes advantage of the fact that the CDR3
region of the immunoglobulin heavy chain is extremely
diverse, so that when the region is PCR amplified the
resultant fragment sizes follow a Gaussian distribution,
providing that the starting material contains over 300 B
cells. A change in diversity of the population can be
detected by deviation from the normal distribution. Most
spectratypes of a control group aged under 50 years show
little variation. However, about a third of the older group,
aged 86 to 94, has significant deviation from normal,
indicating a loss of diversity of the B cell population in the
peripheral blood. This loss of diversity correlated strongly
with the health status of the individual, a loss of diversity
being associated with those classified as "frail" [24]. Fur-
ther studies will have to be undertaken to determine the
exact relationship between loss of diversity and frailty,
and whether the loss of B cell diversity substantially affects
the response to antigen challenge. However it is becoming
clearer that the B cell population is substantially altered in
old age and that this has a significant contribution to
immunosenescence.Immunity & Ageing 2009, 6:10 http://www.immunityageing.com/content/6/1/10
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Conclusion
In the elderly, many alterations of both innate and
acquired immunity have been described. These alterations
are generally viewed as a deterioration of immunity, lead-
ing to the use of the term immunosenescence. This proc-
ess is also characterized by chronic inflammatory status.
Hence, immunosenescence is responsible for the
increased susceptibility of elderly to infectious diseases as
well as being at the root of the biological mechanisms
responsible for inflammatory age-related diseases [1-4]. A
long life in a healthy, vigorous, youthful body has always
been one of humanity's greatest dreams. Hence a better
understanding of immunosenescence, and the develop-
ment of new strategies to counteract it, are essential, not
only for anti-ageing strategies aiming at rejuvenation, but,
more importantly, with the aim of prolonging healthy life
by preventing infectious diseases and thereby improving
the quality of life in later years [25,26].
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